Literature DB >> 25978159

Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Brad Spellberg1, Robert A Bonomo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25978159      PMCID： PMC4620434          DOI： 10.1097/CCM.0000000000001029

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  21 in total

1.  Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.

Authors:  Hao-Yuan Lee; Chyi-Liang Chen; Si-Ru Wu; Chih-Wei Huang; Cheng-Hsun Chiu
Journal:  Crit Care Med       Date:  2014-05       Impact factor: 7.598

2.  Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.

Authors:  Chang-Pan Liu; Shou-Chuan Shih; Nai-Yu Wang; Alice Y Wu; Fang-Ju Sun; Shan-Fan Chow; Te-Li Chen; Tsong-Rong Yan
Journal:  J Microbiol Immunol Infect       Date:  2014-11-11       Impact factor: 4.399

3.  A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.

Authors:  A Nutman; R Glick; E Temkin; M Hoshen; R Edgar; T Braun; Y Carmeli
Journal:  Clin Microbiol Infect       Date:  2014-08-11       Impact factor: 8.067

4.  Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.

Authors:  Yu-long Zheng; Yu-feng Wan; Li-yang Zhou; Mao-lin Ye; Shu Liu; Chuan-qin Xu; Yuan-qiang He; Jian-hui Chen
Journal:  Am J Infect Control       Date:  2013-03-21       Impact factor: 2.918

5.  Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.

Authors:  Arnold Louie; Christine Fregeau; Weiguo Liu; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

Review 6.  Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis.

Authors:  E V Lemos; F P de la Hoz; T R Einarson; W F McGhan; E Quevedo; C Castañeda; K Kawai
Journal:  Clin Microbiol Infect       Date:  2013-10-17       Impact factor: 8.067

7.  Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.

Authors:  Aristine Cheng; Yu-Chung Chuang; Hsin-Yun Sun; Wang-Huei Sheng; Chia-Jui Yang; Chun-Hsing Liao; Po-Ren Hsueh; Jia-Ling Yang; Ni-Jiin Shen; Jann-Tay Wang; Chien-Ching Hung; Yee-Chun Chen; Shan-Chwen Chang
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

8.  Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.

Authors:  Yu-Chung Chuang; Chien-Yu Cheng; Wang-Huei Sheng; Hsin-Yun Sun; Jann-Tay Wang; Yee-Chun Chen; Shan-Chwen Chang
Journal:  BMC Infect Dis       Date:  2014-02-24       Impact factor: 3.090

9.  Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia.

Authors:  Se Yoon Park; Jin Woo Choo; Soon Ha Kwon; Shi Nae Yu; Eun Jung Lee; Tae Hyong Kim; Eun Ju Choo; Min Huok Jeon
Journal:  Infect Chemother       Date:  2013-09-27

10.  Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea.

Authors:  Young Kyoung Park; Kyong Ran Peck; Hae Suk Cheong; Doo Ryeon Chung; Jae Hoon Song; Kwan Soo Ko
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883
View more
  9 in total

Review 1.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

2.  In Vitro Activity of Peptide Antibiotics in Combination With Other Antimicrobials on Extensively Drug-Resistant Acinetobacter baumannii in the Planktonic and Biofilm Cell.

Authors:  Qianlin Meng; Fei Lin; Baodong Ling
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

3.  In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  João Pires; Thissa N Siriwardena; Michaela Stach; Regula Tinguely; Sara Kasraian; Francesco Luzzaro; Stephen L Leib; Tamis Darbre; Jean-Louis Reymond; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

4.  Extensively drug-resistant Acinetobacter baumannii and Proteeae association in a Romanian intensive care unit: risk factors for acquisition.

Authors:  Delia Muntean; Monica Licker; Florin Horhat; Victor Dumitrașcu; Dorel Săndesc; Ovidiu Bedreag; Dorina Dugăeșescu; Dan A Coșniță; Anca Krasta; Luminița Bădițoiu
Journal:  Infect Drug Resist       Date:  2018-11-08       Impact factor: 4.003

5.  Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis.

Authors:  Olexiy Sagan; Ruslan Yakubsevitch; Krassimir Yanev; Roman Fomkin; Emily Stone; Daniel Hines; John O'Donnell; Alita Miller; Robin Isaacs; Subasree Srinivasan
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

6.  Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects.

Authors:  Jason D Lickliter; Kenneth Lawrence; John O'Donnell; Robin Isaacs
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

7.  Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment.

Authors:  Murat Cokol; Chen Li; Sriram Chandrasekaran
Journal:  PLoS Comput Biol       Date:  2018-12-31       Impact factor: 4.475

8.  In vitro activity of biofilm inhibitors in combination with antibacterial drugs against extensively drug-resistant Acinetobacter baumannii.

Authors:  Qin Peng; Fei Lin; Baodong Ling
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

Review 9.  Empiric Treatment in HAP/VAP: "Don't You Want to Take a Leap of Faith?"

Authors:  Khalil Chaïbi; Gauthier Péan de Ponfilly; Laurent Dortet; Jean-Ralph Zahar; Benoît Pilmis
Journal:  Antibiotics (Basel)       Date:  2022-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.